Milosevic, Michael F <br/><br/>
Sorafenib Increases Tumor Hypoxia in Cervical Cancer Patients Treated With Radiation Therapy: Results of a Phase 1 Clinical Study.  [electronic resource] 

 -  International journal of radiation oncology, biology, physics  Jan 2016 
 - 111-117 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1879-355X 
<br/><br/><label>Standard No.: </label>10.1016/j.ijrobp.2015.09.009  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Angiogenesis Inhibitors--administration & dosage<br/>Antineoplastic Agents--administration & dosage<br/>Biomarkers<br/>Brachytherapy--methods<br/>Carcinoma, Squamous Cell--blood supply<br/>Cell Hypoxia<br/>Chemoradiotherapy--methods<br/>Cisplatin--administration & dosage<br/>Drug Administration Schedule<br/>Early Termination of Clinical Trials<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Niacinamide--administration & dosage<br/>Oxygen--metabolism<br/>Partial Pressure<br/>Phenylurea Compounds--administration & dosage<br/>Radiation Tolerance--drug effects<br/>Sorafenib<br/>Time Factors<br/>Tumor Burden<br/>Uterine Cervical Neoplasms--blood supply